Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

Fausto Roila, David Warr, Matti Aapro, Rebecca A. Clark-Snow, Larry Einhorn, Richard J. Gralla, Jorn Herrstedt, Mitsue Saito, Maurizio Tonato

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Purpose: An update of the recommendations for the prophylaxis of delayed emesis induced by moderately emetogenic chemotherapy discussed during the third Perugia Consensus Conference (June 2009) sponsored by MASCC-ESMO was presented. The review considered new studies published since the second consensus conference (April 2004). Methods: An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English. Results: Overall, nine randomized controlled studies were included: four evaluating NK1 receptor antagonists, one palonosetron, and four dopamine receptor antagonists. Conclusions: In patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant is suggested to prevent delayed emesis. In patients who do not receive aprepitant for the prophylaxis for acute emesis and in which palonosetron is recommended, a multiday oral dexamethasone is the preferred treatment for the prevention of delayed emesis. Levels of evidence and of consensus for both recommendations are moderate.

Original languageEnglish (US)
JournalSupportive Care in Cancer
Volume19
Issue numberSUPPL. 1
DOIs
StatePublished - Mar 2011
Externally publishedYes

Fingerprint

aprepitant
Vomiting
Drug Therapy
Dexamethasone
Serotonin 5-HT3 Receptor Antagonists
Receptors, Serotonin, 5-HT3
Dopamine Antagonists
Anthracyclines
PubMed
Cyclophosphamide
Nausea

Keywords

  • Delayed emesis
  • Dopamine receptor antagonists
  • Moderately emetogenic chemotherapy
  • Neurokinin antagonists
  • Serotonin antagonists

ASJC Scopus subject areas

  • Oncology

Cite this

Roila, F., Warr, D., Aapro, M., Clark-Snow, R. A., Einhorn, L., Gralla, R. J., ... Tonato, M. (2011). Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only). Supportive Care in Cancer, 19(SUPPL. 1). https://doi.org/10.1007/s00520-010-1039-y

Delayed emesis : Moderately emetogenic chemotherapy (single-day chemotherapy regimens only). / Roila, Fausto; Warr, David; Aapro, Matti; Clark-Snow, Rebecca A.; Einhorn, Larry; Gralla, Richard J.; Herrstedt, Jorn; Saito, Mitsue; Tonato, Maurizio.

In: Supportive Care in Cancer, Vol. 19, No. SUPPL. 1, 03.2011.

Research output: Contribution to journalArticle

Roila, F, Warr, D, Aapro, M, Clark-Snow, RA, Einhorn, L, Gralla, RJ, Herrstedt, J, Saito, M & Tonato, M 2011, 'Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only)', Supportive Care in Cancer, vol. 19, no. SUPPL. 1. https://doi.org/10.1007/s00520-010-1039-y
Roila, Fausto ; Warr, David ; Aapro, Matti ; Clark-Snow, Rebecca A. ; Einhorn, Larry ; Gralla, Richard J. ; Herrstedt, Jorn ; Saito, Mitsue ; Tonato, Maurizio. / Delayed emesis : Moderately emetogenic chemotherapy (single-day chemotherapy regimens only). In: Supportive Care in Cancer. 2011 ; Vol. 19, No. SUPPL. 1.
@article{d8718548fc1149e4aaff4ec64a01a94a,
title = "Delayed emesis: Moderately emetogenic chemotherapy (single-day chemotherapy regimens only)",
abstract = "Purpose: An update of the recommendations for the prophylaxis of delayed emesis induced by moderately emetogenic chemotherapy discussed during the third Perugia Consensus Conference (June 2009) sponsored by MASCC-ESMO was presented. The review considered new studies published since the second consensus conference (April 2004). Methods: An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English. Results: Overall, nine randomized controlled studies were included: four evaluating NK1 receptor antagonists, one palonosetron, and four dopamine receptor antagonists. Conclusions: In patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant is suggested to prevent delayed emesis. In patients who do not receive aprepitant for the prophylaxis for acute emesis and in which palonosetron is recommended, a multiday oral dexamethasone is the preferred treatment for the prevention of delayed emesis. Levels of evidence and of consensus for both recommendations are moderate.",
keywords = "Delayed emesis, Dopamine receptor antagonists, Moderately emetogenic chemotherapy, Neurokinin antagonists, Serotonin antagonists",
author = "Fausto Roila and David Warr and Matti Aapro and Clark-Snow, {Rebecca A.} and Larry Einhorn and Gralla, {Richard J.} and Jorn Herrstedt and Mitsue Saito and Maurizio Tonato",
year = "2011",
month = "3",
doi = "10.1007/s00520-010-1039-y",
language = "English (US)",
volume = "19",
journal = "Supportive Care in Cancer",
issn = "0941-4355",
publisher = "Springer Verlag",
number = "SUPPL. 1",

}

TY - JOUR

T1 - Delayed emesis

T2 - Moderately emetogenic chemotherapy (single-day chemotherapy regimens only)

AU - Roila, Fausto

AU - Warr, David

AU - Aapro, Matti

AU - Clark-Snow, Rebecca A.

AU - Einhorn, Larry

AU - Gralla, Richard J.

AU - Herrstedt, Jorn

AU - Saito, Mitsue

AU - Tonato, Maurizio

PY - 2011/3

Y1 - 2011/3

N2 - Purpose: An update of the recommendations for the prophylaxis of delayed emesis induced by moderately emetogenic chemotherapy discussed during the third Perugia Consensus Conference (June 2009) sponsored by MASCC-ESMO was presented. The review considered new studies published since the second consensus conference (April 2004). Methods: An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English. Results: Overall, nine randomized controlled studies were included: four evaluating NK1 receptor antagonists, one palonosetron, and four dopamine receptor antagonists. Conclusions: In patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant is suggested to prevent delayed emesis. In patients who do not receive aprepitant for the prophylaxis for acute emesis and in which palonosetron is recommended, a multiday oral dexamethasone is the preferred treatment for the prevention of delayed emesis. Levels of evidence and of consensus for both recommendations are moderate.

AB - Purpose: An update of the recommendations for the prophylaxis of delayed emesis induced by moderately emetogenic chemotherapy discussed during the third Perugia Consensus Conference (June 2009) sponsored by MASCC-ESMO was presented. The review considered new studies published since the second consensus conference (April 2004). Methods: An online search was used conducting PubMed and the search terms moderately, chemotherapy, and emesis with a restriction to papers in English. Results: Overall, nine randomized controlled studies were included: four evaluating NK1 receptor antagonists, one palonosetron, and four dopamine receptor antagonists. Conclusions: In patients receiving a combination of anthracycline plus cyclophosphamide treated with a combination of aprepitant, a 5-HT3 receptor antagonist and dexamethasone to prevent acute nausea and vomiting, aprepitant is suggested to prevent delayed emesis. In patients who do not receive aprepitant for the prophylaxis for acute emesis and in which palonosetron is recommended, a multiday oral dexamethasone is the preferred treatment for the prevention of delayed emesis. Levels of evidence and of consensus for both recommendations are moderate.

KW - Delayed emesis

KW - Dopamine receptor antagonists

KW - Moderately emetogenic chemotherapy

KW - Neurokinin antagonists

KW - Serotonin antagonists

UR - http://www.scopus.com/inward/record.url?scp=79953302387&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79953302387&partnerID=8YFLogxK

U2 - 10.1007/s00520-010-1039-y

DO - 10.1007/s00520-010-1039-y

M3 - Article

C2 - 21132332

AN - SCOPUS:79953302387

VL - 19

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

SN - 0941-4355

IS - SUPPL. 1

ER -